Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul R Skolnik

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
European Cytokine Network|June 28, 2007
Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjectsGregory B Pott, Carrie A Sailer, Reuven Porat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2012
A low-effort, clinic-wide intervention improves attendance for HIV primary careLytt I Gardner, Gary Marks, Jason A Craw, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
European Cytokine Network|June 28, 2007
Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjectsGregory B Pott, Carrie A Sailer, Reuven Porat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2012
A low-effort, clinic-wide intervention improves attendance for HIV primary careLytt I Gardner, Gary Marks, Jason A Craw, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 4